Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 2, 2015, Pages 149-154

  Rognoni, Carla ^a   Marchetti, Monia ^b   Quaglini, Silvana ^c   Liberato, Nicola Lucio ^d  

^a BOCCONI UNIVERSITY   (Italy)

^b CARDINAL MASSAIA HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d Azienda Ospedaliera della Provincia di Pavia   (Italy)

Author keywords

Atrial fibrillation; Cost effectiveness analysis; Edoxaban; Pharmacoeconomic analysis; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; EDOXABAN; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; WARFARIN;

ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CHEMICALLY INDUCED; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; ITALY; MARKOV CHAIN; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; STATISTICS AND NUMERICAL DATA; STROKE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; COST-BENEFIT ANALYSIS; HUMANS; INTRACRANIAL HEMORRHAGES; ITALY; MARKOV CHAINS; PYRIDINES; QUALITY-ADJUSTED LIFE YEARS; STROKE; THIAZOLES; WARFARIN;

EID: 84933527492     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1104-3     Document Type: Article

References (24)

1. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen W-K (2013) Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS guideline recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 127(18):1916–1926
2. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P, Kirchhof P (2012) 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33(21):2719–2747
3. Kansal AR, Zheng Y, Pokora T, Sorensen SV (2013) Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best Pract Res Clin Haematol 26(2):225–237
4. Limone BL, Baker WL, Kluger J, Coleman CI (2013) Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models. PLoS One 8(4):1–15
5. Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU, Peng S, Roskell N, Sorensen SV (2012) Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost 108(4):672–682
6. Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P (2014) Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation. Clin Ther 36(2):192-210.e20
7. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104
8. Rognoni C, Marchetti M, Quaglini S, Liberato NL (2014) Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig 34(1):9–17
9. Monz BU, Connolly SJ, Korhonen M, Noack H, Pooley J (2013) Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study. Int J Cardiol 168(3):2540–2547
10. Gage BF, Cardinalli AB, Owens DK (1998) Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 29(6):1083–1091
11. Sullivan PW, Arant TW, Ellis SL, Ulrich H (2006) The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics 24(10):1021–1033
12. Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL (2010) A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 28(1):61–74
13. Fattore G, Torbica A, Susi A, Giovanni A, Benelli G, Gozzo M, Toso V (2012) The social and economic burden of stroke survivors in Italy: a prospective, incident-based, multi-centre cost of illness study. BMC Neurol 12:137–147
14. Fedele F, D’Ambrosi A, Bruno N, Caira C, Brasolin B, Mancone M (2011) Cost-effectiveness of levosimendan in patients with acute heart failure. J Cardiovasc Pharmacol 58(4):363–366
15. O’Brien CL, Gage BF (2005) Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 293:699–706
16. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM (2004) The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 164(8):880–884
17. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154(13):1449–1457
18. Ariesen MJ, Claus SP, Rinkel GJ, Algra A (2003) Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 34(8):2060–2065
19. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22):2864–2870
20. National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. 2008. Available from: http://www.nice.org.uk/media/b52/a7/tamethodsguideupdatedjune2008.pdf Accessed January 10, 2014
21. Frick K, Neissen L, Bridges J, Walker D, Wilson RF, Bass EB (2012) Usefulness of economic evaluation data in systematic reviews of evidence. Agency for healthcare research and quality (US) Report no. 12(13)
22. Danzon P, Towse A, Mestre-Ferrandiz J (2013) Value based differential pricing: efficient prices for drugs in a global context. Health Econ. doi:10.1002/hec.3021
23. Hall PS, McCabe C, Brown JM, Cameron DA (2010) Health economics in drug development: efficient research to inform healthcare funding decisions. Eur J Cancer 46(15):2674–2680
24. van Nooten F, Holmstrom S, Green J, Wiklund I, Odeyemi IA, Wilcox TK (2012) Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research. Drug Discov Today 17(11–12):615–622